Unlocking the Power of AI with Human-Centered Biological Data
Researchers across the Wyss Institute generate deeply-characterized, human-relevant datasets that offer a powerful foundation for AI applications in biomedicine, sustainability, and beyond. Through the integration of patient samples and advanced tissue models – such as Organ Chips and organoids – with high-throughput imaging and state-of-the-art multi-omics technologies, we produce complex and high-resolution data. These datasets capture dynamic biological responses across transcriptomic, proteomic, and metabolomic layers – often from clinical samples or experimentally controlled conditions – which is critical for effectively training machine learning models with real-world translational potential. Further, the Wyss’ advanced tissue models can serve as a pre-clinical validation platform for model predictions.
The AI DataHub, an effort of the Wyss Translational AI Catalyst, was established to structure, curate, and mobilize these data assets for high-impact partnerships. By accessing our datasets and co-developing analytical strategies with tech companies, pharma, biotech, hospitals, and government collaborators, we aim to accelerate discovery and sustain further innovation at the Institute. The Wyss’ AI DataHub enables partners to tap into our unique biological systems, data infrastructure, and deep biology expertise – unlocking opportunities for drug discovery, predictive toxicology, biomarker development, drug efficacy, and more. With a strong record in translational science and a commitment to collaborative engagement, the Wyss Institute is an ideal partner for AI-driven R&D.
Integrating AI to tackle Grand Challenges
The Wyss Institute’s Sustainable Futures Initiative integrates AI with synthetic biology and bioengineering to address urgent environmental challenges. From AI-guided enzyme design for breaking down pollutants to real-time digital twins that optimize sustainable biomanufacturing, our teams generate high-resolution, biologically rich datasets that power intelligent, adaptive solutions. These platforms not only accelerate discovery but also create strategic opportunities for partners to advance next-generation sustainability technologies.
The Wyss Institute is advancing a new model for our Cancer Solutions Grand Challenge by generating richly-annotated, multi-omic datasets directly from real-world clinical samples. Through collaborations with leading Harvard hospitals, our teams integrate proteomics, genomics, imaging, and pathology into unified datasets that can power AI-driven insights in diagnosis, therapeutic response, and companion diagnostics development. This initiative fills a critical gap for biopharma and companion diagnostic developers seeking high-quality, clinically contextualized molecular data to accelerate precision oncology.
The Wyss Institute’s Women’s Health Catalyst is advancing innovation in diagnostics, therapeutics, and medical devices to address long-overlooked conditions that uniquely or disproportionately affect women. By integrating multi-omic profiling, Organ Chip models, and targeted drug delivery platforms, we generate rich datasets tailored to autoimmune diseases, gynecologic cancers, cardiovascular and neurodegenerative conditions, and reproductive health. Our translational pipeline and partnerships with clinicians and industry accelerate the path from discovery to impact – with the goal of meeting long overlooked needs in women’s health.